Janux Therapeutics, Inc. Research and Development Expense
Janux Therapeutics, Inc. (JANX) reported Research and Development Expense of $30.99 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Janux Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $30.99M, a 10.59% decline year-over-year.
- Janux Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $26.81M, a 7.02% increase year-over-year.
- Janux Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $31.55M, a 51.63% increase year-over-year.
- Janux Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $34.63M, a 86.04% increase year-over-year.
- Janux Therapeutics, Inc. research and development expense for fiscal 2025 was $125.90M, a 84.09% increase from fiscal 2024.
- Janux Therapeutics, Inc. research and development expense for fiscal 2024 was $68.39M, a 24.52% increase from fiscal 2023.
- Janux Therapeutics, Inc. research and development expense for fiscal 2023 was $54.92M, a 2.77% increase from fiscal 2022.
- Janux Therapeutics, Inc. research and development expense for fiscal 2022 was $53.44M, a 103.69% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.99M 10-Q · filed 2026-08-06 | $57.81M 10-Q · filed 2026-08-06 | $89.36M derived: sum of 3 quarters · filed 2026-08-06 | $123.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $26.81M 10-Q · filed 2026-05-07 | $58.36M derived: sum of 2 quarters · filed 2026-05-07 | $92.99M derived: sum of 3 quarters · filed 2026-05-07 | $127.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $31.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $66.18M derived: sum of 2 quarters · filed 2026-02-26 | $100.84M derived: sum of 3 quarters · filed 2026-08-06 | $125.90M 10-K · filed 2026-02-26 |
| 2025-09-30 | $34.63M 10-Q · filed 2025-11-06 | $69.29M derived: sum of 2 quarters · filed 2026-08-06 | $94.35M 10-Q · filed 2025-11-06 | $115.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $34.66M 10-Q · filed 2026-08-06 | $59.72M 10-Q · filed 2026-08-06 | $80.53M derived: sum of 3 quarters · filed 2026-08-06 | $99.14M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $25.05M 10-Q · filed 2026-05-07 | $45.86M derived: sum of 2 quarters · filed 2026-05-07 | $64.47M derived: sum of 3 quarters · filed 2026-05-07 | $79.37M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $20.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $39.42M derived: sum of 2 quarters · filed 2026-02-26 | $54.32M derived: sum of 3 quarters · filed 2026-02-26 | $68.39M 10-K · filed 2026-02-26 |
| 2024-09-30 | $18.61M 10-Q · filed 2025-11-06 | $33.51M derived: sum of 2 quarters · filed 2025-11-06 | $47.58M 10-Q · filed 2025-11-06 | $59.82M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $14.90M 10-Q · filed 2025-08-07 | $28.97M 10-Q · filed 2025-08-07 | $41.21M derived: sum of 3 quarters · filed 2026-02-26 | $53.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $14.07M 10-Q · filed 2025-05-08 | $26.31M derived: sum of 2 quarters · filed 2026-02-26 | $38.20M derived: sum of 3 quarters · filed 2026-02-26 | $53.13M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $12.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $24.13M derived: sum of 2 quarters · filed 2026-02-26 | $39.06M derived: sum of 3 quarters · filed 2026-02-26 | $54.92M 10-K · filed 2026-02-26 |
| 2023-09-30 | $11.89M 10-Q · filed 2024-11-06 | $26.82M derived: sum of 2 quarters · filed 2024-11-06 | $42.68M 10-Q · filed 2024-11-06 | $58.12M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $14.92M 10-Q · filed 2024-08-07 | $30.79M 10-Q · filed 2024-08-07 | $46.22M derived: sum of 3 quarters · filed 2025-02-27 | $59.96M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $15.87M 10-Q · filed 2024-05-08 | $31.30M derived: sum of 2 quarters · filed 2025-02-27 | $45.04M derived: sum of 3 quarters · filed 2025-02-27 | $59.12M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $15.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $29.17M derived: sum of 2 quarters · filed 2025-02-27 | $43.26M derived: sum of 3 quarters · filed 2025-02-27 | $53.44M 10-K · filed 2025-02-27 |
| 2022-09-30 | $13.74M 10-Q · filed 2023-11-07 | $27.82M derived: sum of 2 quarters · filed 2023-11-07 | $38.01M 10-Q · filed 2023-11-07 | $49.18M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $14.09M 10-Q · filed 2023-08-08 | $24.27M 10-Q · filed 2023-08-08 | $35.44M derived: sum of 3 quarters · filed 2023-08-08 | $43.84M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $10.18M 10-Q · filed 2023-05-09 | $21.35M derived: sum of 2 quarters · filed 2023-05-09 | $29.76M derived: sum of 3 quarters · filed 2023-05-09 | $34.50M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $11.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $19.57M derived: sum of 2 quarters · filed 2023-03-10 | $24.31M derived: sum of 3 quarters · filed 2023-03-10 | $26.24M 10-K · filed 2023-03-10 |
| 2021-09-30 | $8.41M 10-Q · filed 2022-11-10 | $13.14M derived: sum of 2 quarters · filed 2022-11-10 | $15.07M 10-Q · filed 2022-11-10 | $16.05M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $4.74M 10-Q · filed 2022-08-09 | $6.66M 10-Q · filed 2022-08-09 | $7.65M derived: sum of 3 quarters · filed 2022-08-09 | $8.48M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $1.93M 10-Q · filed 2022-05-10 | $2.91M derived: sum of 2 quarters · filed 2022-05-10 | $3.74M derived: sum of 3 quarters · filed 2022-05-10 | $4.42M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $985.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $1.82M derived: sum of 2 quarters · filed 2022-03-18 | $2.49M derived: sum of 3 quarters · filed 2022-03-18 | $3.04M 10-K · filed 2022-03-18 |
| 2020-09-30 | $834.00K 10-Q · filed 2021-11-09 | $1.51M derived: sum of 2 quarters · filed 2021-11-09 | $2.06M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $673.00K 10-Q · filed 2021-08-10 | $1.22M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |